Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients

The therapeutic goal for hepatitis B virus (HBV) infection is HBs antigen (HBsAg) seroclearance, which is achieved through 48-week pegylated interferon (Peg-IFN) therapy. This study aimed to identify predictive biomarkers for sustained HBsAg reduction by analyzing serum microRNAs. Twenty-two consecu...

詳細記述

保存先:
書誌詳細
出版年:Int J Mol Sci
主要な著者: Fujita, Koji, Mimura, Shima, Iwama, Hisakazu, Nakahara, Mai, Oura, Kyoko, Tadokoro, Tomoko, Nomura, Takako, Tani, Joji, Yoneyama, Hirohito, Morishita, Asahiro, Oryu, Makoto, Himoto, Takashi, Nishitsuji, Hironori, Shimotohno, Kunitada, Omata, Masao, Masaki, Tsutomu
フォーマット: Artigo
言語:Inglês
出版事項: MDPI 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073286/
https://ncbi.nlm.nih.gov/pubmed/30004437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19071940
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料